Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia

Eur J Heart Fail. 2017 May;19(5):682-685. doi: 10.1002/ejhf.806.

Authors

David D Berg¹, Muthiah Vaduganathan¹, Anju Nohria¹, Matthew S Davids², Edwin P Alyea², Matthew Torre³, Robert F Padera Jr³

Affiliations

¹ Division of Cardiovascular Medicine Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
² Department of Medical Oncology Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 28485549
DOI: 10.1002/ejhf.806

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Biopsy
Electrocardiography
Fatal Outcome
Humans
Immunity, Cellular / drug effects*
Ipilimumab / adverse effects*
Ipilimumab / therapeutic use
Leukemia, Myelomonocytic, Chronic / drug therapy*
Male
Myocarditis / diagnosis
Myocarditis / etiology*
Myocarditis / immunology
Myocardium / pathology*
T-Lymphocytes / immunology*

Substances

Ipilimumab